中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系
Expression of EZH2 in Chinese Ewing sarcoma patients and its relationship with clinicopathological parameters and prognosis

DOI: 10.6040/j.issn.1671-7554.0.2016.446

Keywords: 临床病理学,zeste增强子同源物2,预后,免疫组织化学法,尤文肉瘤,Ki-67,
Ki-67,Ewing sarcoma,Immunohistochemistry,Prognosis,Enhancer of zeste homolog 2,Clinicopathology

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer[J]. EMBO J, 2003, 22(20): 5323-5335.
[2]	Huqun, Ishikawa R, Zhang J, et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer[J]. Cancer, 2012, 118(6): 1599-1606.
[3]	Borinstein SC, Beeler N, Block JJ, et al. A decade in banking ewing sarcoma: a report from the Childrens oncology group[J]. Front Oncol, 2013, 3: 57. doi:10.3389/fonc.2013.00057.
[4]	Paulussen M, Bielack S, Jurgens H, et al. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up[J]. Ann Oncol, 2009, 20(Suppl 4): 140-142.
[5]	Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer[J]. Int J Biol Sci, 2012, 8(1): 59-65.
[6]	Tang SH, Huang HS, Wu HU, et al. Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo[J]. Oncotarget, 2014, 5(21): 10342-10355.
[7]	Lin YW, Ren LL, Xiong H, et al. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer[J]. J Pathol, 2013, 230(3): 277-290.
[8]	Lu N, Lin T, Wang L, et al. Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma[J]. Tumour Biol, 2015, 36(5): 3843-3852.
[9]	Montgomery ND, Yee D, Chen A, et al. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation[J]. Curr Biol, 2005, 15(10): 942-947.
[10]	Lopez-Guerrero JA, Machado I, Scotlandi K, et al. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewings sarcoma family of tumors[J]. Int J Cancer, 2011, 128(5): 1139-1150.
[11]	Rhodes DR, Sanda MG, Otte AP, et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer[J]. J Natl Cancer Inst, 2003, 95(9): 661-668.
[12]	Zhu Q, Zhang L, Li X, et al. Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia[J]. Tumour Biol, 2016, 37(8): 11409-11420.
[13]	Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewings sarcoma initiation program in primary human mesenchymal stem cells[J]. Cancer Res, 2008, 68(7): 2176-2185.
[14]	Surdez D, Benetkiewicz M, Perrin V, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth[J]. Cancer Res, 2012, 72(17): 4494-4503.
[15]	Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2[J]. Cancer Cell, 2010, 18(2): 185-197.
[16]	Crea F, Hurt EM, Farrar WL. Clinical significance of Polycomb gene expression in brain tumors[J]. Mol cancer, 2010, 9: 265. doi: 10.1186/1476-4598-9-265.
[17]	Benard A, Goossens-Beumer IJ, Van Hoesel AQ, et al. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer[J]. PLoS One, 2014, 9(9): 108265. doi: 10.1371/journal.pone.0108265.
[18]	Chen DL, Zhang DS, Lu YX, et al. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer[J]. Oncotarget, 2015, 6(13): 10868-10879.
[19]	Liu H, Liu Y, Liu W, et al. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma[J]. Nat Commun, 2015, 6:8494. doi: 10.1038/ncomms 9494.
[20]	Selvanathan SP, Graham GT, Erkizan HV, et al. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing[J]. PNAS, 2015, 112(11): 1307-1316.
[21]	Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immunol, 1984, 133(4): 1710-1715.
[22]	Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer[J]. Cancer Sci, 2006, 97(6): 484-491.
[23]	刘宝岳, 杨郁, 杜娟, 等. EWS易等位分离探针荧光原位杂交和免疫组织化学抗体(FLI-1和CD99)在尤文肉瘤/原始神经外胚层肿瘤诊断中的价值[J]. 北京大学学报(医学版), 2008, 40(4): 358-362. LIU Baoyue, YANG Yu, DU Juan, et al. Application of the in situ hybridization with EWS dual-color break-apart fluorescence probe and anti-CD99 and anti-FIL-1 antibodies in the diagnosis of Ewing sarcoma/primitive neuroectodermal tumor[J]. Journal of Peking University(Health Sciences), 2008, 40(4): 358-362.
[24]	董玉兰, 杨向红, 高英贤, 等. Ki-67及p53蛋白在口腔鳞状上皮肿瘤中的表达及意义[J]. 中国医科大学学报, 2002, 31(2): 16-17. DONG Yulan, YANG Xianghong, GAO Yingxian, et al. Expression of Ki-67 and p53 in oral squamous epithelial tumor and its significance[J]. J Chin Med Univ, 2002, 31(2): 16-17.
[25]	Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors[J]. Cancer Cell, 2007, 11(5): 421-429.
[26]	Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life[J]. Nature, 2011, 469(7330): 343-349.
[27]	Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex[J]. Mol Cell, 2004, 15(1): 57-67.
[28]	Kim KH, Roberts CW. Targeting EZH2 in cancer[J]. Nat Med, 2016, 22(2): 128-134.
[29]	Richter GH, Plehm S, Fasan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation[J]. Proc Natl Sci U S A, 2009, 106(13): 5324-5329.
[30]	Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets[J]. Cancer Res, 2004, 64(22): 8213-8221.
[31]	Von Levetzow C, Jiang X, Gwye Y, et al. Modeling initiation of Ewing sarcoma in human neural crest cells[J]. PLoS One, 2011, 6(4): 19305. doi: 10.1371/journal. pone.0019305.

Full-Text